An article discussing recent change in US innovation policy

I was interviewed and provided written feedback explaining and discussing the proposed reduction of the data exclusivity period for biopharmaceuticals currently available under the newly introduced BPCA (2010). In early 2011 the U.S government had proposed to reduce the available exclusivity periods from 12 to 7 years.